Status:
TERMINATED
Short-term Antibiotic Therapy for Pyelonephritis in Childhood
Lead Sponsor:
IRCCS Burlo Garofolo
Conditions:
Pyelonephritis
Eligibility:
All Genders
1-5 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy of oral ceftibuten for 7 days versus 10 days in acute pyelonephritis in children. The main hypothesis is that the ceftibuten for 7 days will be n...
Detailed Description
Acute pyelonephritis is one of the most common serious bacterial infections in childhood, particularly in young children, with an estimated prevalence in febrile infants of 5.3%. It has been considere...
Eligibility Criteria
Inclusion
- Children aged 1 month to 5 years, with a first episode of pyelonephritis.
Exclusion
- Children less than 1 month, or older than 5 years.
- Relapse of pyelonephritis.
- Sepsis and/or vomiting, or other conditions where it's impossible to administer an oral therapy.
- Allergy to ceftibuten.
- Previous antibiotic therapy for the same infection.
- Long term antibiotic prophylaxis with an antibiotic of the same class, if laboratory antibiotic resistance is shown.
- Children with uncontrolled other disease.
- Complicated pyelonephritis (abscess).
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00724256
Start Date
July 1 2006
End Date
July 1 2010
Last Update
February 17 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute for Child Health Burlo Garofolo
Trieste, Triest, Italy, 34137